id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC9774927
core_pubmed_pmc
The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults
The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults Abstract Abstract Bacterial central nervous system (CNS) infections are serious and carry significant morbidity and mortality. They encompass many syndromes, the most ...
PMC8380870
core_pubmed_pmc
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2 Abstract Abstract A recently published article described the safety, tolerability, and pharmacokinetic profile of molnupiravir (Painter et al. 2021), a novel antiviral...
PMC3165084
core_pubmed_pmc
A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia
A Phase 1 Trial Dose Escalation Study of Tipifarnib on a Week-On, Week-Off Schedule in Relapsed, Refractory or High-Risk Myeloid Leukemia Abstract Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-leukemia activity. We report the results of a phase 1 dose escalation stud...
PMC8167502
core_pubmed_pmc
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial Abstract Background : Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with ...
PMC12582837
core_pubmed_pmc
Mechanism, research progress and warning of the effects of acupuncture at Zusanli point (ST36) on pharmacokinetics: A review
Mechanism, research progress and warning of the effects of acupuncture at Zusanli point (ST36) on pharmacokinetics: A review Abstract In traditional Chinese medicine, acupuncture is considered free of harmful side effects when properly performed. Pharmacokinetics provides a valuable approach to explore how acupuncture ...
PMC4875984
core_pubmed_pmc
Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer
Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer Abstract Researchers have made considerable progress in last few decades in understanding mechanisms underlying pathogenesis of breast cancer, its phenotypes, its molecular and ...
PMC12535240
core_pubmed_pmc
A Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction
A Systematic Review of Population Pharmacokinetics, Safety, and Factors Influencing Trough Concentrations of Voriconazole in Asian Patients with Liver Dysfunction Abstract Abstract Objective This study systematically reviews recent research on voriconazole (VRC) use in Asian patients with liver dysfunction to provide a...
PMC7419427
core_pubmed_pmc
Murine Thigh Microdialysis to Evaluate the Pharmacokinetic/Pharmacodynamic Integration of Cefquinome Against Actinobacillus pleuropneumoniae
Murine Thigh Microdialysis to Evaluate the Pharmacokinetic/Pharmacodynamic Integration of Cefquinome Against Actinobacillus pleuropneumoniae Abstract This study aimed to explore the application of microdialysis in pharmacokinetic (PK)/pharmacodynamic (PD) integration of cefquinome against Actinobacillus pleuropneumonia...
PMC10381519
core_pubmed_pmc
New Perspective for Drug–Drug Interaction in Perioperative Period
New Perspective for Drug–Drug Interaction in Perioperative Period Abstract In this review, we aim to discuss current information on drug interactions in the perioperative period. During this period, patients receive several drugs that may interact with each other and affect the efficacy and safety of the treatment. The...
PMC12180079
core_pubmed_pmc
Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1
Insights Into Atorvastatin Pharmacokinetics in Rats Reveal Regulation of CYP3A1 by Humanization of SLCO2B1 Abstract ABSTRACT The organic anion transporting polypeptide (OATP) 2B1 is expressed in pharmacokinetically relevant organs such as the liver, the kidney, and the small intestine and it is known to transport a bro...
PMC11481060
core_pubmed_pmc
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand
Exploring the clinical factors affecting lithium dose and plasma level and the effect of brand Abstract Abstract Background: Optimal use of lithium involves adjustment of the dose, to keep the plasma level within the narrow, recommended range. Brand-specific prescribing has long been considered critical to achieving th...
PMC10649793
core_pubmed_pmc
Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice
Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice Abstract Abstract Background Despite the promising efficacy of immune checkpoint blockers (ICB), tumor resistance and immune-related adverse events hinder their success in cancer treatment. To address these challenges, intratumoral d...
PMC4983396
core_pubmed_pmc
Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies
Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies Abstract Abstract Anti-drug antibodies induced by biologic therapeutics often impact drug pharmacokinetics, pharmacodynamics response, clinical efficacy, and patient safety. It is critical to assess the immunogenicity risk of potential b...
PMC3258012
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus Abstract Abstract Introduction The goal of insulin therapy in patients with either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) is to match as closely as possible normal physiologic insuli...
PMC10190255
core_pubmed_pmc
Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
Systematic Evaluation of Pharmacokinetic Models for Model-Informed Precision Dosing of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy Abstract ABSTRACT The altered pharmacokinetics of renally cleared drugs such as meropenem in critically ill patients receiving continuous renal repl...
PMC11561661
core_pubmed_pmc
Pharmacokinetics of PP353 , a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first‐in‐human, Phase 1b, open‐label, single‐dose study
Pharmacokinetics of PP353 , a formulation of linezolid for intervertebral disc administration, in patients with chronic low back pain and Modic change Type 1: A first‐in‐human, Phase 1b, open‐label, single‐dose study Abstract Abstract Background Bacterial infection of the intervertebral disc is difficult to treat becau...
PMC4285808
core_pubmed_pmc
Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive
Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive Abstract Abstract Objective: To determine the relative bioavailability of ethinyl estradiol (EE) and gestodene (GSD) after application of a novel transdermal cont...
PMC10875779
core_pubmed_pmc
Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies
Understanding the nebulisation of antibiotics: the key role of lung microdialysis studies Abstract Background Nebulisation of antibiotics is a promising treatment for ventilator-associated pneumonia (VAP) caused by multidrug-resistant organisms. Ensuring effective antibiotic concentrations at the site of infection in t...
PMC12436539
core_pubmed_pmc
Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients
Serum Concentration of Apixaban in Relation to Renal Function in Older Hospitalized Patients Abstract Abstract Background and Objective Apixaban is the most prescribed direct-acting oral anticoagulant drug. According to its product information, clearance is only partially renal. However, little is known about the impac...
PMC11993231
core_pubmed_pmc
Pharmacokinetics and Side Effects of Δ 9 -Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD
Pharmacokinetics and Side Effects of Δ 9 -Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD Abstract Introduction Chronic kidney disease (CKD) affects approximately 10% of the global population and is associated with a large symptom burden. Medicinal cannabis is advised against in patients w...
PMC10261012
core_pubmed_pmc
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer Abstract EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerab...
PMC4006077
core_pubmed_pmc
A missed opportunity – consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient
A missed opportunity – consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient Abstract Background Levetiracetam is a frequently used drug in the therapy of partial onset, myoclonic and generalized tonic-clonic seizures. The main route of elimination is via the kidneys, which eliminate 6...
PMC11116716
core_pubmed_pmc
Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsis
Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsis Abstract Introduction: Biapenem is a carbapenem antibiotic widely used in Asia, can be used for the treatment of adults and children with infections due to susceptible bacteria. Although biapenem is utilized in th...
PMC11930543
core_pubmed_pmc
Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia
Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia Abstract ABSTRACT Sitafloxacin is one of the oral respiratory quinolones for the treatment of community‐acquired pneumonia. The pharmacokinetic (PK) changes of s...
PMC7911130
core_pubmed_pmc
The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry
The Protein-Binding Behavior of Platinum Anticancer Drugs in Blood Revealed by Mass Spectrometry Abstract Abstract Cisplatin and its analogues are widely used as chemotherapeutic agents in clinical practice. After being intravenously administrated, a substantial amount of platinum will bind with proteins in the blood. ...
PMC6306724
core_pubmed_pmc
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives
Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives Abstract Abstract In the past decades, many efforts have been made to individualize medical treatments, taking into account molecular profiles and the individual genetic background. The development of molecularly targeted dr...
PMC12642743
core_pubmed_pmc
First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma
First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma Abstract Abstract Background: Platinum-resistant high-grade serous ovarian carcinomas (HGSOC) are associated with poor therapeutic outcomes. While HGSOC frequently metastasizes to th...
PMC9557049
core_pubmed_pmc
Pharmacokinetics and pharmacodynamics of isopropoxy benzene guanidine against Clostridium perfringens in an intestinal infection model
Pharmacokinetics and pharmacodynamics of isopropoxy benzene guanidine against Clostridium perfringens in an intestinal infection model Abstract Abstract This study aimed to evaluate the antibacterial activity of isopropoxy benzene guanidine (IBG) against C. perfringens based on pharmacokinetics/pharmacodynamics (PK/PD)...
PMC10420276
core_pubmed_pmc
Prescribed Versus Taken Polypharmacy and Drug–Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study
Prescribed Versus Taken Polypharmacy and Drug–Drug Interactions in Older Cardiovascular Patients during the COVID-19 Pandemic: Observational Cross-Sectional Analytical Study Abstract The study aimed to assess clinical pharmacology patterns of prescribed and taken medications in older cardiovascular patients using elect...
PMC8082150
core_pubmed_pmc
Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis
Minireview on Novel Anti-infectious Treatment Options and Optimized Drug Regimens for Sepsis Abstract Abstract Sepsis, a life-threatening organ dysfunction caused by a dysregulated response to infection is a major public health concern, as it is a leading cause of mortality and critical illness worldwide. Antibiotics a...
PMC8956739
core_pubmed_pmc
A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens
A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens Abstract Abstract The emergence of multidrug-resistant (MDR) Gram-negative pathogens is an urgent global medical challenge. The old polymyxin lipopeptide antibiotics (polymyxin B and colistin) are often the only therapeutic optio...
PMC6019484
core_pubmed_pmc
Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers Abstract Abstract Background: Vicagrel is a novel anti-platelet drug and hydrolyzed to the same intermediate as clopidogrel via esterase, instead of CYP2C19. Here we report the first cl...
PMC10066622
core_pubmed_pmc
Assessing the Knowledge and Perceptions of Medical Students After Using Kahoot! in Pharmacology Practical Sessions at King Abdulaziz University, Jeddah
Assessing the Knowledge and Perceptions of Medical Students After Using Kahoot! in Pharmacology Practical Sessions at King Abdulaziz University, Jeddah Abstract Objective Game-based e-learning (GbEl) has been shown to motivate students significantly, encourage learning, and improve academic performance. Kahoot! is one ...
PMC6591615
core_pubmed_pmc
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection Abstract Fluoroquinolones are group A drugs in tuberculosis guidelines. We aim to compare the culture conversion between new-generation (levofloxacin and moxifloxacin) and ol...
PMC11551477
core_pubmed_pmc
An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction
An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction Abstract Abstract The study objective was to validate febuxostat dosage and administration in pediatric patients with hyperuri...
PMC8186476
core_pubmed_pmc
Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection
Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection Abstract Abstract Immunomodulatory and analgesic effects of dexamethasone are clinically well established, and this synthetic corticosteroid acts as an agonist of glucocorticoid receptors. Early results of t...
PMC7477386
core_pubmed_pmc
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial Abstract Abstract Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose...
PMC10590806
core_pubmed_pmc
Mechanistic inhibition of gastric cancer-associated bacteria Helicobacter pylori by selected phytocompounds: A new cutting-edge computational approach
Mechanistic inhibition of gastric cancer-associated bacteria Helicobacter pylori by selected phytocompounds: A new cutting-edge computational approach Abstract Background Helicobacter pylori ( H. pylori ) is a persistent bacterial inhabitant in the stomachs of approximately half the global populace. This bacterium is d...
PMC3902632
core_pubmed_pmc
Therapeutic drug monitoring for imatinib: Current status and Indian experience
Therapeutic drug monitoring for imatinib: Current status and Indian experience Abstract Abstract Imatinib is the current gold standard for treatment of chronic myeloid leukemia (CML). Recent pharmacokinetic studies have shown considerable variability in trough concentrations of imatinib due to variations in its metabol...
PMC7935830
core_pubmed_pmc
Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model
Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model Abstract Abstract Purpose A variety of diagnostic methods are available to validate the performance of population pharmacokinetic models. Internal validation, which applies these methods to the model bui...
PMC6402530
core_pubmed_pmc
Mathematical modeling and computational prediction of cancer drug resistance
Mathematical modeling and computational prediction of cancer drug resistance Abstract Abstract Diverse forms of resistance to anticancer drugs can lead to the failure of chemotherapy. Drug resistance is one of the most intractable issues for successfully treating cancer in current clinical practice. Effective clinical ...
PMC10537526
core_pubmed_pmc
Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol
Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated with Tramadol Abstract Abstract Following the contraindication of codeine use in children, increasing use of tramadol has been observed in pain management protocols. However, tramadol’s pharmacokinetics (PK) and pharmacodynamics are influenced by cyt...
PMC12587609
core_pubmed_pmc
Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo
Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo Abstract ABSTRACT A key challenge in preclinical tuberculosis drug development is identifying optimal antibiotic combinations. Drug interactions are complex because one drug may affect...
PMC9365383
core_pubmed_pmc
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab Abstract Abstract Purpose: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, includi...
PMC12808451
core_pubmed_pmc
Neoantigen immune responses in healthy volunteers: insights from multiple integrated keyhole limpet hemocyanin challenge studies on repeated immunization and response covariates
Neoantigen immune responses in healthy volunteers: insights from multiple integrated keyhole limpet hemocyanin challenge studies on repeated immunization and response covariates Abstract Introduction Investigational immunomodulatory drugs are often initially investigated in healthy volunteers, which lack drug-target en...
PMC12420565
core_pubmed_pmc
Semaglutide - properties, action and chromatographic analysis
Semaglutide - properties, action and chromatographic analysis Abstract Objectives This review assessed the selected information on semaglutide’s activity, its potential for the treatment of various diseases, and its pharmacokinetics. It is intended as a guide for future research. Chromatographic procedures used for the...
PMC8470483
core_pubmed_pmc
Bidirectional Influences of Cranberry on the Pharmacokinetics and Pharmacodynamics of Warfarin with Mechanism Elucidation
Bidirectional Influences of Cranberry on the Pharmacokinetics and Pharmacodynamics of Warfarin with Mechanism Elucidation Abstract Cranberry is a dietary supplement popularly used for the prophylaxis of urinary tract infection. Interestingly, cranberry–warfarin interactions in clinical reports have shown bidirectional ...
PMC4784825
core_pubmed_pmc
Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery
Topotecan Delivery to the Optic Nerve after Ophthalmic Artery Chemosurgery Abstract Extraocular retinoblastoma is a major challenge worldwide, especially in developing countries. Current treatment involves the administration of systemic chemotherapy combined with radiation, but there is a clear need for improvement of ...
PMC8772788
core_pubmed_pmc
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model Abstract We evaluated piperacillin-tazobactam and tobramycin regimens against Pseudomonas aeruginosa i...
PMC10317528
core_pubmed_pmc
Microbiologic Cure with a Simplified Dosage of Intravenous Colistin in Adults: A Retrospective Cohort Study
Microbiologic Cure with a Simplified Dosage of Intravenous Colistin in Adults: A Retrospective Cohort Study Abstract Abstract Purpose Colistin’s FDA weight-based dosing (WBD) and frequency are both expressed in a broad range. Therefore, a simplified fixed-dose regimen (SFDR) of intravenous colistin based on three body-...
PMC6466860
core_pubmed_pmc
A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia
A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia Abstract Despite advancements in therapy, pneumonia remains the leading cause of death due to infectious diseases. Novel treatment strategies are desperately needed to optimize the antimicrobial therapy of patie...
PMC6390583
core_pubmed_pmc
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494) Abstract Abstract Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in t...
PMC9381887
core_pubmed_pmc
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases Abstract Abstract Infliximab dosage de‐escalation without prior knowledge of drug concentrations may put patients at risk for underexposure and trigger the loss of response. A single‐model appro...
PMC9834004
core_pubmed_pmc
Biodistribution and pharmacokinetic evaluation of Korean Red Ginseng components using radioisotopes in a rat model
Biodistribution and pharmacokinetic evaluation of Korean Red Ginseng components using radioisotopes in a rat model Abstract Abstract Background Although many studies have evaluated the efficacy and pharmacokinetics of Korean Red Ginseng (KRG) components (Rg1, Rb1, Rg3, Rd, etc.), few have examined the in vivo pharmacok...
PMC4989500
core_pubmed_pmc
Determination of diclofenac concentrations in human plasma using a sensitive gas chromatography mass spectrometry method
Determination of diclofenac concentrations in human plasma using a sensitive gas chromatography mass spectrometry method Abstract Abstract Background A gas chromatography mass spectrometry (GCMS) method for the determination of diclofenac in human plasma has been developed and validated. Results This method utilizes he...
PMC7946665
core_pubmed_pmc
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia Abstract Purpose This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refr...
PMC12104385
core_pubmed_pmc
Corchorus olitorius exhibits antiproliferative potential supported by metabolic profiling and integrative biological analyses
Corchorus olitorius exhibits antiproliferative potential supported by metabolic profiling and integrative biological analyses Abstract Abstract Herbal nutraceuticals could be employed as alternative or complementary routes for alleviating cancer. Corchorus olitorius (Malvaceae) was employed traditionally in the managem...
PMC5910468
core_pubmed_pmc
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects Abstract Abstract Introduction Semaglutide is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes. This tri...
PMC5553100
core_pubmed_pmc
Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets
Phase I study evaluating the safety, tolerability and pharmacokinetics of a novel oral dissolvable film containing dexamethasone versus Fortecortin dexamethasone tablets Abstract ABSTRACT Introduction : Systemic corticosteroids are anti-inflammatory agents with dexamethasone among the most potent in the class. Within (...
PMC7856757
core_pubmed_pmc
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study Abstract Background The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypert...
PMC3402269
core_pubmed_pmc
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes Abstract Abstract OBJECTIVE Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes. Gevokizumab is a novel, human-engineered monoclonal anti–IL-1β antibody. We evalua...
PMC9344630
core_pubmed_pmc
Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study
Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study Abstract Background A prospective interventional study comparing outcomes in critically ill patients receiving intermittent infusion (II) or conti...
PMC12098381
core_pubmed_pmc
Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients
Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients Abstract Abstract Background Docetaxel is commonly used in breast cancer chemotherapy. The previous drug dose is generally calculated based on body surface area (BSA). However, the metabolism varies great...
PMC11933637
core_pubmed_pmc
Are All Pharmacokinetic Equations Created Equal? A Comparative Analysis of Trapezoidal and Non-Trapezoidal Methods for Estimating Day 1 Area Under the Curve in Adult Hospitalized Patients with Staphylococcus aureus Bacteremia
Are All Pharmacokinetic Equations Created Equal? A Comparative Analysis of Trapezoidal and Non-Trapezoidal Methods for Estimating Day 1 Area Under the Curve in Adult Hospitalized Patients with Staphylococcus aureus Bacteremia Abstract Abstract Introduction This study compared the calculated vancomycin area under the cu...
PMC12783228
core_pubmed_pmc
Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum
Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum Abstract Abstract Background and Objective Tenofovir (TFV)-based regimens are backbones of both HIV treatment...
PMC7003773
core_pubmed_pmc
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis Abstract Abstract Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections caused by susceptible gram‐positive microorganisms. This analysis represents the update of the population pharmacokinetics (po...
PMC10223637
core_pubmed_pmc
Generic Workflow to Predict Medicine Concentrations in Human Milk Using Physiologically-Based Pharmacokinetic (PBPK) Modelling—A Contribution from the ConcePTION Project
Generic Workflow to Predict Medicine Concentrations in Human Milk Using Physiologically-Based Pharmacokinetic (PBPK) Modelling—A Contribution from the ConcePTION Project Abstract Abstract Women commonly take medication during lactation. Currently, there is little information about the exposure-related safety of materna...
PMC12425505
core_pubmed_pmc
Peptide-based drug as atherosclerosis multitarget therapy from Lytechinus variegatus spine: An in silico study
Peptide-based drug as atherosclerosis multitarget therapy from Lytechinus variegatus spine: An in silico study Abstract Abstract Atherosclerosis is a leading cardiovascular disease characterized by the buildup of plaques within arterial walls. The aim of this study was to investigate the potential of peptides derived f...
PMC10376599
core_pubmed_pmc
Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients
Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients Abstract Obesity is a significant global public health concern that is associated with an elevated risk of comorbidities as well as severe postoperative and nosocomial infections. The treatment of infections in critically ill obese patients ...
PMC10870500
core_pubmed_pmc
Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trial
Impact of model-informed precision dosing in adults receiving vancomycin via continuous infusion: a randomized, controlled clinical trial Abstract Background Vancomycin is a commonly prescribed antibiotic to treat gram-positive infections. The efficacy of vancomycin is known to be directly related to the pharmacokineti...
PMC12939220
core_pubmed_pmc
In Silico Molecular Docking and Pharmacokinetic Evaluation of Cannabinoid Derivatives as Multi-Target Inhibitors for EGFR, VEGFR-1, and VEGFR-2 Proteins
In Silico Molecular Docking and Pharmacokinetic Evaluation of Cannabinoid Derivatives as Multi-Target Inhibitors for EGFR, VEGFR-1, and VEGFR-2 Proteins Abstract Abstract Cancer therapy development increasingly focuses on multi-target approaches to inhibit key proteins involved in tumor growth and angiogenesis. This st...
PMC11529615
core_pubmed_pmc
Safety and efficacy of personalised versus standard dosing of linezolid in patients with sepsis (SePkLin): a pragmatic, multicentre, randomised, controlled and superiority clinical trial protocol
Safety and efficacy of personalised versus standard dosing of linezolid in patients with sepsis (SePkLin): a pragmatic, multicentre, randomised, controlled and superiority clinical trial protocol Abstract Abstract Introduction Linezolid is a broadly used antibiotic to treat complicated infections caused by gram-positiv...
PMC12664903
core_pubmed_pmc
A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects
A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects Abstract ABSTRACT Budesonide is a first‐line inhaled glucocorticoid (ICS) for asthma treatment in adults and children. The purpose of this study was to compare the pharmacoki...
PMC3706980
core_pubmed_pmc
Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization
Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization Abstract Introduction Prior in vivo murine studies suggest circadian oscillations for hematopoietic stem cell release, which are maintained following administratio...
PMC8551406
core_pubmed_pmc
CRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics
CRISPR-Cas9: A method for establishing rat models of drug metabolism and pharmacokinetics Abstract The 2020 Nobel Prize in Chemistry recognized CRISPR-Cas9, a super-selective and precise gene editing tool. CRISPR-Cas9 has an obvious advantage in editing multiple genes in the same cell, and presents great potential in d...
PMC12649284
core_pubmed_pmc
Assessment of Telisotuzumab Vedotin Drug–Drug Interaction Potential Using Physiologically‐Based Pharmacokinetic Modeling and Simulations
Assessment of Telisotuzumab Vedotin Drug–Drug Interaction Potential Using Physiologically‐Based Pharmacokinetic Modeling and Simulations Abstract Abstract Telisotuzumab vedotin (Teliso‐V; ABBV‐399) is an antibody‐drug conjugate (ADC) comprised of the c‐Met targeting antibody telisotuzumab (ABT‐700) conjugated to the po...
PMC10719486
core_pubmed_pmc
Pharmacokinetic/LDL‐C and exposure–response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies
Pharmacokinetic/LDL‐C and exposure–response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies Abstract Abstract Tafolecimab, a novel fully human monoclonal antibody targeting PCSK9, has been assessed in Chinese healthy volunteers and patients with hypercholester...
PMC4767189
core_pubmed_pmc
Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression
Designing More Efficient Preclinical Experiments: A Simulation Study in Chemotherapy-Induced Myelosupression Abstract Abstract A new more efficient preclinical study design (referred to as a compact design) is proposed that removes the need for satellite animals for the collection of toxicokinetic (TK) data by sampling...
PMC11503159
core_pubmed_pmc
A doxorubicin loaded chitosan–poloxamer in situ implant for the treatment of breast cancer †
A doxorubicin loaded chitosan–poloxamer in situ implant for the treatment of breast cancer † Abstract Abstract Breast cancer is a serious concern for many women worldwide. Drug-loaded implants have shown several benefits over systemic administrations. To provide anti-cancer drugs with controlled release and reduced sys...
PMC9024849
core_pubmed_pmc
Pharmacokinetics of DA-6886, A New 5-HT 4 Receptor Agonist, in Rats
Pharmacokinetics of DA-6886, A New 5-HT 4 Receptor Agonist, in Rats Abstract DA-6886 is a novel serotonin (5-hydroxytrypamine [5-HT]) receptor 4 agonist for the potential treatment of constipation-predominant irritable bowel syndrome. The purpose of this study was to validate the quantitative assay of DA-6886 in rat pl...
PMC5099554
core_pubmed_pmc
Effect of fermented red ginseng on cytochrome P450 and P‐glycoprotein activity in healthy subjects, as evaluated using the cocktail approach
Effect of fermented red ginseng on cytochrome P450 and P‐glycoprotein activity in healthy subjects, as evaluated using the cocktail approach Abstract Aims We assessed the drug interaction profile of fermented red ginseng with respect to the activity of major cytochrome (CYP) P450 enzymes and of a drug transporter prote...
PMC10703963
core_pubmed_pmc
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males Abstract Abstract Introduction Depression, anxiety, and/or panic disorder are often comorbid and have a complex etiology mediated through the same neuronal net...
PMC5698755
core_pubmed_pmc
Biosimilars: Key regulatory considerations and similarity assessment tools
Biosimilars: Key regulatory considerations and similarity assessment tools Abstract Abstract A biosimilar drug is defined in the US Food and Drug Administration (FDA) guidance document as a biopharmaceutical that is highly similar to an already licensed biologic product (referred to as the reference product) notwithsta...
PMC12129647
core_pubmed_pmc
Therapeutic Targeting of the α7 Nicotinic Receptor: Challenges and Prospects for Cognitive Improvement in Alzheimer's and Schizophrenia
Therapeutic Targeting of the α7 Nicotinic Receptor: Challenges and Prospects for Cognitive Improvement in Alzheimer's and Schizophrenia Abstract ABSTRACT The α7 nicotinic acetylcholine receptor (α7 nAChR) has emerged as a key target for treating cognitive dysfunction in neurological disorders such as Alzheimer's diseas...
PMC3421442
core_pubmed_pmc
INDI: a computational framework for inferring drug interactions and their associated recommendations
INDI: a computational framework for inferring drug interactions and their associated recommendations Abstract Abstract Inferring drug–drug interactions (DDIs) is an essential step in drug development and drug administration. Most computational inference methods focus on modeling drug pharmacokinetics, aiming at interac...
PMC4650854
core_pubmed_pmc
In silico evaluation and exploration of antibiotic tuberculosis treatment regimens
In silico evaluation and exploration of antibiotic tuberculosis treatment regimens Abstract Background Improvement in tuberculosis treatment regimens requires selection of antibiotics and dosing schedules from a large design space of possibilities. Incomplete knowledge of antibiotic and host immune dynamics in tubercul...
PMC10500909
core_pubmed_pmc
Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation
Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation Abstract Abstract Background Few drug dosing recommendations for patients receiving home hemodialysis (HHD) have been published which has hindered the adoption of HHD. HHD regimens vary widely and diffe...
PMC7232861
core_pubmed_pmc
Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children
Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children Abstract Abstract Poor adherence to seasonal malaria chemoprevention (SMC) might affect the protective effectiveness of SMC. Here, we evaluated the population pharmacokinetic properties ...
PMC8332564
core_pubmed_pmc
Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure Abstract Abstract Objective The objective of this study was to assess the pharmacokinetic and pharmacodynamic profiles and safety of edoxaban in patients with nonvalvular atrial fibrillation (N...
PMC11745015
core_pubmed_pmc
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer
A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer Abstract Abstract Background Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis, necessitating the investigation of novel treatments and targets. T...
PMC12523034
core_pubmed_pmc
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers
Safety, pharmacokinetics and pharmacodynamics of Plozasiran in Chinese healthy volunteers Abstract Background Plozasiran (VSA001, ARO-APOC3) is an RNA interference therapy that targets Apolipoprotein C3 (APOC3), a key regulator of lipoprotein metabolism. The study aimed at assessing the safety, tolerability, pharmacoki...
PMC5051241
core_pubmed_pmc
Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished children
Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished children Abstract Objectives: Studies on antimalarial kinetics in children or adults who are undernourished or malnourished are both limited and have yielded conflicting results. ...
PMC5096281
core_pubmed_pmc
Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion
Characterization and Bioavailability Study of Baicalin-mesoporous Carbon Nanopowder Solid Dispersion Abstract Background: Baicalin is the main bioactive constitute of the dried roots of Scutellaria baicalensis and possesses various biological activities. However, the poor water solubility and low oral bioavailability l...
PMC8452302
core_pubmed_pmc
Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling
Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling Abstract Abstract Quantitative assessment of drug‐drug interactions (DDIs) involving breast cancer resistance protein (BCRP) inhibition is challenged by overlapping substrate/i...
PMC11276774
core_pubmed_pmc
A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies
A New Tailored Nanodroplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant and Anti-Inflammatory Efficacies Abstract Abstract Astaxanthin (ATX) is a carotenoid nutraceutical with poor bioavailability due to its high lipophilicity. We tested a new tailored nanodroplet capable of solubilizi...
PMC10452628
core_pubmed_pmc
Effect of Leflunomide–Metal Complexes on ROS, TNF, and Brain Indolamines in Comparison with Anti-Depressants as Adjunct Therapy in Rheumatoid Arthritic Model
Effect of Leflunomide–Metal Complexes on ROS, TNF, and Brain Indolamines in Comparison with Anti-Depressants as Adjunct Therapy in Rheumatoid Arthritic Model Abstract Leflunomide is an isoxazole immunomodulating drug used to treat rheumatoid arthritis (RA). It is adopted as a metal-containing molecule to proceed with s...
PMC9953224
core_pubmed_pmc
Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders
Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders Abstract Abstract Background and objective: The determination of pharmacokinetic properties of new chemical entities is a key step in the proces...
PMC12505664
core_pubmed_pmc
Enflicoxib for the long-term management of canine osteoarthritis—External validation of a population pharmacokinetic model in dogs with osteoarthritis
Enflicoxib for the long-term management of canine osteoarthritis—External validation of a population pharmacokinetic model in dogs with osteoarthritis Abstract Introduction Enflicoxib is a cyclooxygenase-2 (Cox-2) selective non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammatio...
PMC10937462
core_pubmed_pmc
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report Abstract Abstract Drug-induced liver injury (DILI) is a potential adverse event of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS), as well as of methylprednisolo...
PMC12114857
core_pubmed_pmc
In Silico Evaluation of the Biopharmaceutical and Pharmacokinetic Behavior of Metronidazole from Coated Colonic Release Matrix Tablets †
In Silico Evaluation of the Biopharmaceutical and Pharmacokinetic Behavior of Metronidazole from Coated Colonic Release Matrix Tablets † Abstract Abstract Background: Physiologically based biopharmaceutics modeling (PBBM) models can help to predict drug release and in vivo absorption behaviors. Colon drug delivery syst...